文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

骨髓增生异常综合征感染风险呈动态变化且由免疫驱动

Infection risk in myelodysplastic syndromes is dynamic and immune driven.
PubMed 文献 · Blood Adv · 2026-09-01

该回顾性研究纳入708例MDS患者,分析二十年间感染相关住院的发生率、微生物学、时间动态和预测因素。感染相关住院与总生存较差独立相关,中性粒细胞减少是主要驱动因素,但免疫功能障碍独立增加易感性,抗菌药物耐药性出现令人担忧的变化。

要点

  • 感染相关住院与MDS患者总生存较差独立相关。
  • 中性粒细胞减少是感染风险主要驱动因素,但免疫功能障碍独立增加易感性。
  • 阿扎胞苷治疗患者中近四分之三感染相关住院发生在前六个周期内。

核心结论

  • MDS中的感染是动态的、具有预后重要性的并发症,由血细胞减少、治疗和免疫功能障碍驱动。

研究设计与样本

  • 回顾性研究纳入708例MDS患者,分析二十年间感染相关住院的发生率、微生物学、时间动态和预测因素。

主要发现

  • 78.8%(n=558)的患者需要住院,其中69.9%为感染相关。
  • 多变量Cox比例风险模型显示,合并症负担、红细胞输注依赖、较高IPSS-R风险、化疗或干细胞移植暴露以及严重中性粒细胞减少独立预测感染。
  • 阿扎胞苷治疗患者中71.4%经历感染相关住院,近四分之三发生在前六个周期内。
  • 近期感染或严重中性粒细胞减少(<0.5×10⁹/L)使后续感染风险增加2.47倍。
  • 14%的革兰阴性菌感染产超广谱β-内酰胺酶,21%的铜绿假单胞菌分离株对哌拉西林-他唑巴坦耐药,耐万古霉素肠球菌患病率从14%增至46%。

临床怎么用

  • 支持时间适应性风险分层、针对性预防和抗菌药物管理,尤其在早期治疗和高风险疾病阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infection is a major cause of morbidity and mortality in myelodysplastic syndromes (MDS), yet infection risk remains incompletely defined in the contemporary treatment era. We conducted a retrospective study of 708 patients with MDS to characterize the incidence, microbiology, temporal dynamics, and predictors of infection-related hospitalization over two decades. Overall, 78.8% (n=558) of patients required hospitalization, of which 69.9% were infection related. Infection-related hospitalization was independently associated with inferior overall survival. In multivariable Cox proportional hazards model, comorbidity burden, red blood cell transfusion dependence, higher IPSS-R risk, exposure to chemotherapy or stem cell transplantation, and severe neutropenia independently predicted infection. Among azacitidine-treated patients, 71.4% experienced infection-related hospitalization, with nearly three-quarters occurring within the first six cycles, identifying a critical early vulnerability window. Neutropenia remained the dominant driver of infection risk; however, immune dysfunction independently increased susceptibility. Low monocyte counts, cytokine dysregulation, and TP53 mutations identified high-risk patients despite preserved neutrophil counts, reflecting impaired myeloid reserve. Consistent with this dynamic vulnerability, recent infection or severe neutropenia (<0.5×10⁹/L) increased subsequent infection risk by 2.47-fold. We observed a concerning shift in antimicrobial resistance, with 14% of Gram-negative infections producing extended-spectrum beta-lactamases, 21% of Pseudomonas aeruginosa isolates resistant to piperacillin-tazobactam, and vancomycin-resistant enterococci prevalence increasing from 14% to 46%. Together, these findings identify infection in MDS as a dynamic, prognostically important complication driven by cytopenia, treatment, and immune dysfunction. This supports time-adapted risk stratification, targeted prevention, and antimicrobial stewardship, particularly during early treatment and high-risk disease phase.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pradhan A, Chhetri R, Selby P, et al. Infection risk in myelodysplastic syndromes is dynamic and immune driven. Blood Adv. 2026. PMID: 42678914. doi:10.1182/bloodadvances.2026019689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。